← Leaderboards
Rima L McLeod
University Of Chicago
$13,565,835
Attributed
$13,565,835
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–13$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$13,565,835 · 6
By mechanism
U01$8,634,870 · 2
R01$4,915,772 · 2
P41$15,193 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Toxoplasma Gondii”
- L David Sibley · Washington University$42,221,391
- John C Boothroyd · Stanford University$21,342,994
- Christopher A Hunter · University Of Pennsylvania$20,595,527
- Michael W White · University Of California Riverside$17,265,886
- Vernon Bruce Carruthers · Johns Hopkins University$15,672,870
- Gary E Ward · University Of Vermont & St Agric College$14,197,597
Research focus
Toxoplasma GondiiParasitesCongenital InfectionToxoplasmosisProgramsBaseBinding (Molecular Function)Laboratory MousePathway InteractionsAntibodiesPathogenRecombinantsBioterrorismToxoplasmaChicagoImmune ResponseInfectionHandDesignOrganismLifePyrimethamineAffectToxic Effect
Grant awards (26)
Optimizing Inhibitors of T. gondii ENR$805,607
U01 · FY2013 · AI · contact PI
Optimizing Inhibitors of T. gondii ENR$854,765
U01 · FY2012 · AI · contact PI
Towards a Vaccine to Prevent Toxoplasmosis$810,759
U01 · FY2012 · AI · contact PI
Optimizing Inhibitors of T. gondii ENR$870,087
U01 · FY2011 · AI · contact PI
Towards a Vaccine to Prevent Toxoplasmosis$827,305
U01 · FY2011 · AI · contact PI
CHARACTERIZATION OF KEY REGULATORY PROTEINS IN T GONDII$12,768
P41 · FY2011 · RR · contact PI
Optimizing Inhibitors of T. gondii ENR$881,657
U01 · FY2010 · AI · contact PI
Towards a Vaccine to Prevent Toxoplasmosis$835,272
U01 · FY2010 · AI · contact PI
Treatment of Congenital Toxoplasmosis$190,476
R01 · FY2010 · AI · contact PI
CHARACTERIZATION OF KEY REGULATORY PROTEINS IN T GONDII$2,425
P41 · FY2010 · RR · contact PI
Optimizing Inhibitors of T. gondii ENR$996,821
U01 · FY2009 · AI · contact PI
Towards a Vaccine to Prevent Toxoplasmosis$842,962
U01 · FY2009 · AI · contact PI
Treatment of Congenital Toxoplasmosis$192,399
R01 · FY2009 · AI · contact PI
Towards a Vaccine to Prevent Toxoplasmosis$909,635
U01 · FY2008 · AI · contact PI
Treatment of Congenital Toxoplasmosis$195,233
R01 · FY2008 · AI · contact PI
Treatment of Congenital Toxoplasmosis$206,611
R01 · FY2007 · AI · contact PI
NOVEL APICOMPLEXAN METABOLISM AND ORGANELLE TRANSIT$440,385
R01 · FY2005 · AI
TREATMENT OF CONGENITAL TOXOPLASMOSIS$435,578
R01 · FY2004 · AI
NOVEL APICOMPLEXAN METABOLISM AND ORGANELLE TRANSIT$427,558
R01 · FY2004 · AI
TREATMENT OF CONGENITAL TOXOPLASMOSIS$422,893
R01 · FY2003 · AI
NOVEL APICOMPLEXAN METABOLISM AND ORGANELLE TRANSIT$415,105
R01 · FY2003 · AI
NOVEL APICOMPLEXAN METABOLISM AND ORGANELLE TRANSIT$403,015
R01 · FY2002 · AI
TREATMENT OF CONGENITAL TOXOPLASMOSIS$376,539
R01 · FY2002 · AI
NOVEL APICOMPLEXAN METABOLISM AND ORGANELLE TRANSIT$411,607
R01 · FY2001 · AI
TREATMENT OF CONGENITAL TOXOPLASMOSIS$403,208
R01 · FY2001 · AI
TREATMENT OF CONGENITAL TOXOPLASMOSIS$395,165
R01 · FY2000 · AI